#China #Shanghai #Senaparib #IMPACT Therapeutics #Pharmanovia

IMPACT Therapeutics Partners with Pharmanovia for Senaparib

IMPACT Therapeutics, a notable biotechnology firm listed on the Hong Kong Stock Exchange, announced an exclusive licensing agreement with Pharmanovia, a global specialty pharmaceutical company, on July 31, 2026. This partnership aims to broaden the reach of Senaparib, a potent cancer treatment, in several key regions including Europe, the Middle East and North Africa, as well as Australia and New Zealand.

Key Details of the Agreement

The agreement marks a significant milestone for both companies. Pharmanovia is granted exclusive rights to manufacture, develop, and commercialize Senaparib specifically for maintenance therapy in advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancers. This partnership extends Senaparib’s availability to a total of 66 countries, encompassing not only the European Union member states but also the United Kingdom, Norway, and other regions.

Under the terms of the agreement, IMPACT is set to receive an upfront payment along with substantial milestone payments contingent on regulatory approvals and sales performance. The total potential financial benefits of this partnership could amount to EUR 423.5 million. Furthermore, IMPACT will earn tiered royalties, which can rise to 25% based on net sales of the product.

Expanding Patient Access

This collaboration represents IMPACT's commitment to providing accessible oncology treatments outside of China. Currently, Senaparib has been approved as a first-line maintenance therapy in China, and with this licensing agreement, it is anticipated that approval in Europe will come in the second half of 2026—furthering the prospects for patient access to this innovative treatment.

By leveraging Pharmanovia's established infrastructure and specialized expertise, the commercialization process of Senaparib is likely to occur more rapidly after receiving regulatory approvals. This is crucial as it aims to fulfill the pressing medical needs of patients suffering from advanced cancer conditions, thereby improving outcomes in a timely manner.

About Senaparib and Its Impact

Senaparib, known scientifically as IMP4297, is a highly selective PARP1/2 inhibitor developed by IMPACT. Its unique features include a well-defined safety profile and remarkable target selectivity, providing a promising treatment option for patients following platinum-based chemotherapy. Since its approval in January 2025 in China, it has been included in the National Reimbursement Drug List, making it more accessible to patients requiring maintenance therapy.

As of August 2025, the European Medicines Agency accepted the Marketing Authorization Application for Senaparib, setting the stage for its introduction in the global market.

About IMPACT Therapeutics

Established in 2009, IMPACT Therapeutics focuses on advancing precision anti-cancer therapies, utilizing synthetic lethality approaches. The company has built a robust pipeline of PARP inhibitors, including senaparib, demonstrated success in providing treatment solutions to patients with significant unmet needs. Their strategic partnerships with global biotech firms further solidify their commitment to optimizing cancer treatment options.

Conclusion

The partnership between IMPACT Therapeutics and Pharmanovia represents a significant step toward enhancing global patient access to innovative cancer therapies. By focusing on key markets and utilizing effective commercialization strategies, this collaboration hopes to deliver impactful treatment solutions that address present medical needs, fostering better health outcomes for patients battling advanced cancers.